NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

NCT01932125

CompletedPhase 4

Sponsor: Hoffmann-La Roche

Conditions: Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms

Interventions: Bevacizumab

Countries: India

This multicenter prospective study will evaluate the safety and efficacy of Avastin (bevacizumab) in routine clinical practice in patients with advanced/metastatic epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. Data will be collected from eligible patients until death, withdrawal of consent, loss to follow-up, or study closure.

Eligibility overview

Sex: FEMALE

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Prescribed to receive bevacizumab or already ongoing on treatment with bevacizumab for advanced/metastatic ovarian cancer, fallopian tube cancer or primary peritoneal cancer (FIGO Stage IIIb, IIIc and IV) according to routine clinical practice

Exclusion Criteria:

* Not eligible for treatment with bevacizumab according to the local prescribing information

Locations (13)

Bangalore, Karnataka, India
Banglore, Karnataka, India
Aurangabad, Maharashtra, India
Mumbai, Maharashtra, India
Nagpur, Maharashtra, India
Nashik, Maharashtra, India
Nashik, Maharashtra, India
Pune, Maharashtra, India
Pune, Maharashtra, India
Pune, Maharashtra, India
New Delhi, National Capital Territory of Delhi, India
Kolkata, West Bengal, India
Delhi, India